



Innovations and Translations in Parkinsonism and Related Disorders

Saturday, 1 May 2021

15:00	<p>15:00 - 16:30 Parallel 1: Biomarkers Chair: Etienne Hirsch (France)</p>	<p>15:00 - 16:30 Parallel 2: Technology Based Assessment Chairs: Mark Lew (USA) and Rajesh Pahwa (USA)</p>	<p>15:00 - 16:30 Educational Course 1: Parkinsonian Syndromes Chairs: Zbigniew Wszolek (USA) and Kailash Bhatia (UK)</p>
15:30	<p>1a. Biomarkers in biofluids 1b. Biomarkers in biotissue Pascal Derkinderen (France) 1c. Neuroimaging biomarkers</p>	<p>2a. Digital monitoring tools in Parkinson disease Roongroj Bhidayasiri (Thailand) 2b. Virtual/clinical telemedicine 2c. Digital monitoring tools in chorea</p>	<p>1a. The process of idiopathic neurodegeneration 1b. Genetic causes of parkinsonism (genotype/phenotype correlations) Andreas Puschmann (Sweden) 1c. Etiology and phenomenology of atypical parkinsonian syndromes: diagnosis by observation Kailash Bhatia (UK)</p>
16:00			
16:30	<p>16:30 - 17:00 Break / ePoster visit</p>		
17:00	<p>17:00- 17:30 Opening Ceremony</p>		
17:30	<p>17:30 - 18:00 Kick-off Plenary Lecture: Is Alpha-Synuclein Still the Basis of Parkinson Disease?</p>		
18:00	<p>18:00 - 18:30 Melvin Yahr Lecture: Parkinson Disease and Essential Tremor: How Are They Related? Joseph Jankovic</p>		
18:30	<p>18:30 - 19:00 Break / ePoster visit</p>		
19:00	<p>19:00 - 19:30 Lifetime Achievement Award Lecture: Discovering the Genetic Causes of Parkinson Disease Zbigniew Wszolek</p>		
19:30	<p>19:30 - 20:30 Best of Parkinsonism and Related Disorders and Clinical Parkinsonism and Related Disorders Chairs: Vincenzo Bonifati (Netherlands) and Hubert Fernandez (USA)</p>		
20:00	<p>a. Basic/ translational PRD papers b. Clinical PRD papers Janis Miyasaki (Canada) c. CPRD papers Huifang Shang (China)</p>		
20:30			

Sunday, 2 May 2021

15:00	<p>15:00 - 16:30</p> <p>Parallel 3: Gut Brain Axis Debate Chairs: Teus van Laar (NL) and Filip Scheperjans (Finland)</p>	<p>15:00 - 16:30</p> <p>Parallel 4: Botulinum Toxins: New Indications in Movement Disorders Chairs: Daniel Truong (USA) and Diego Torres-Russotto (USA)</p>	<p>15:00 - 16:30</p> <p>Educational Course 2: Investigations in Movement Disorders Chairs: Mark Hallett (USA) and Ioannis Isaias (Germany)</p>
15:30	<p>3a. Are microbiome changes important? - Yes - Jeffrey Boertien (NL) - No - Discussion, Q&A</p>	<p>4a. Spasticity and sialorrhea Erle Lim (Singapore)</p>	<p>2a. Imaging Ioannis Isaias (Germany)</p>
16:00	<p>3b. Role of fecal transplantation / pre and probiotics: Pro/con - Pro - Fiorella Contarino (NL) - Con - Discussion, Q&A</p>	<p>4b. Monitoring spread of botulinum toxin with ultrasound</p> <p>4c. State of the art including new toxins Dirk Dressler (Germany)</p>	<p>2b. Neurophysiology Mark Hallett (USA)</p> <p>2c. Biomarkers</p>
16:30	<p>16:30 - 17:00 Break / ePoster visit</p>		
17:00	<p>17:00 - 18:30</p> <p>Industry Session #1</p>		<p>17:00 - 18:30</p> <p>Industry Session #2</p>
17:30			
18:00			
18:30	<p>18:30 - 19:00 Break / ePoster visit</p>		
19:00	<p>19:00 - 20:30</p> <p>Parallel 5: Pathophysiology of Parkinsonian Syndromes Chairs: Etienne Hirsch (France) and Erik Wolters (NL)</p>	<p>19:00 - 20:30</p> <p>Parallel 6: Surgical Therapies in Movement Disorders</p>	<p>19:00 - 20:30</p> <p>Educational Course 3: Translational Treatment in Parkinson Disease Chairs: Mark Hirsch (USA)</p>
19:30	<p>5a. Role of protein processing and lysosomal function in Parkinson disease</p> <p>5b. Role of gut, systemic, and CNS inflammation</p>	<p>6a. Deep brain stimulation for dystonia</p> <p>6b. Conventional lesioning surgery vs. Focused ultrasound W. Jeffrey Elias (USA)—conventional lesioning Alfonso Fasano (Canada)—focused ultrasound</p>	<p>3a. Allied health</p> <p>3b. Pharmacotherapy Yaroslau Compta (Spain)</p> <p>3c. Deep brain stimulation and focused ultrasound Yasin Temel (NL)</p>
20:00	<p>5c. Environmental factors in Parkinson disease</p>	<p>6c. Advances in movement disorder surgery</p>	
20:30			

Monday, 3 May 2021

15:00	15:00 - 16:30 Parallel 7: Gene and Cell Based Therapies Chair: Jeffrey Kordower (USA)	15:00 - 16:30 Parallel 8 Debate: Exercise Therapy in Parkinson's Disease Chair: Erwin van Wegen (NL)	15:00 - 16:30 Educational Course 4: Pathophysiology and Treatment in Hyperkinesia Chair: Daniel Truong (USA)
15:30	7a. Influencing mitochondrial and lysosomal dysfunction	8a. Neurophysiology of exercise in PD (motor and non-motor)	4a. Tremor
16:00	7b. Symptomatic treatment based on gene therapy	8b. Physical exercise is neurorestorative in Parkinson's disease: - Yes - Giuseppe Frazzitta (Italy) - No	Sheng-Han Kuo (USA)
	7c. Gene therapy for neurotrophic factors	Discussion Q&A - Led by Giselle Petzinger (USA)	4b. Dystonia 4c. Myoclonus
16:30	16:30 - 16:45 Break / ePoster visit		
17:00	16:45 - 18:15 Industry Session #3		16:45 - 18:15 Industry Session #4
17:30			
18:00			
	18:15 - 18:30 Break / ePoster visit		
18:30	18:30 - 20:00 Plenary 1: Neuropsychiatric Issues in Parkinson Disease Chairs: Rajesh Pahwa (USA) and Iris Sommer (NL)		
19:00	1a. Dementia in Parkinson's disease: features, diagnosis and treatment Murat Emre (Turkey)		
	1b. Depression in PD Annette Schrag (UK)		
19:30	1c. Impulse control disorders in PD Daniel Weintraub (USA)		
20:00	20:00 - 20:15 Break / ePoster visit		
20:30	20:15 - 21:15 Grand Parade of Movement Disorders Video Challenge Chairs: Alberto Albanese (Italy), Kailash Bhatia (UK), Susanne Schneider (Germany), Shinsuke Fujioka (Japan)		
21:00			
21:30			

Tuesday, 4 May 2021

15:00	<p>15:00 - 16:30 Plenary 2: Genetics of Parkinson Disease <i>Chairs: Zbigniew Wszolek (USA) and Eng King Tan (Singapore)</i></p>		
15:30	<p>2a. Monogenetic causes of Parkinson disease <i>Vincenzo Bonifati (NL)</i></p>		
16:00	<p>2b. Genetic variants and susceptibility genes in Parkinson disease <i>Owen Ross (USA)</i></p>		
16:30	<p>2c. GBA and LRRK2: mechanisms for novel Parkinson disease treatments <i>Ziv Gan-Or (Canada)</i></p>		
16:30	<p>16:30 - 17:00 Break / ePoster visit</p>		
17:00	<p>17:00 - 18:30 Parallel 9: Translational Therapies in Movement Disorders <i>Chair: Erik Wolters (NL)</i></p>	<p>17:00 - 18:30 Parallel 10: Balance and Gait Disorders: New Therapeutic Interventions <i>Chairs: Erwin van Wegen (NL) and Mark Hirsch (USA)</i></p>	<p>17:00 - 18:30 Parallel 11: Infusion Therapies in Parkinson Disease <i>Chairs: Teus van Laar (NL) and Tove Henriksen (Denmark)</i></p>
17:30	<p>9a. Autologous stem cell therapies 9b. Vaccine therapies 9c. Growth factor infusions</p>	<p>10a. Update on pathophysiology 10b. Virtual reality, improving freezing 10c. Personalized gait rehabilitation in Parkinson disease <i>Jorik Nonnekes (NL)</i></p>	<p>11a. Pros and cons of infusion therapies 11b. Update on apomorphine infusion <i>Tove Henriksen (Denmark)</i> 11c. Motor and non-motor effects of levodopa-carbidopa intestinal gel infusion</p>
18:00			
18:30	<p>18:30 - 19:00 Break / ePoster visit</p>		
19:00	<p>19:00 - 20:30 Parallel 12: What's New in Hyperkinetic Disorders? <i>Chairs: Mark Lew (USA) and William Ondo (USA)</i></p>	<p>19:00 - 20:30 Parallel 13: Promising Future Therapies <i>Chairs: Stuart Isaacson (USA) and Daniel Kremens (USA)</i></p>	<p>19:00 - 20:30 Parallel 14: Allied Health Rehabilitation in Parkinson Disease <i>Chair: Erwin van Wegen (NL)</i></p>
19:30	<p>12a. What's new in HD/chorea? <i>Oksana Suchowersky (Canada)</i> 12b. What's new in dystonia? <i>Marie Vidailhet (France)</i></p>	<p>13a. Repurposing strategies to prevent or slow Parkinson disease <i>Michael Schwarzschild (USA)</i> 13b. Cannabinoids 13c. Noninvasive brain stimulation <i>Christian Baumann (Switzerland)</i></p>	<p>14a. Allied health update on fine motor skills in Parkinson disease <i>Tim Vanbellingen (Switzerland)</i> 14b. Multi-disciplinary approach to wearing off-related psychiatric symptoms <i>Odile van den Heuvel (NL)</i></p>
20:00	<p>12c. What's new in tremor? <i>Elan Louis (USA)</i> 12d. What's new in tardive dyskinesia?</p>		
20:30	<p>20:30 - 20:40 Closing Words IAPRD President Daniel Truong (USA)</p>		
21:00			